Kidney-Targeted Extracellular Vesicles for Sepsis Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis-associated acute kidney injury lack specificity and effectiveness, with high incidence rates and severe outcomes, and existing extracellular vesicle therapies face challenges in targeted kidney delivery and stable distribution.
Innovation Solution
Modified extracellular vesicles are developed by combining CD5 antigen-like protein expressed on extracellular vesicles secreted by fibroblastic reticular cells with an anchoring peptide, specifically targeting the kidney through genetic engineering and peptide targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for sepsis-associated acute kidney injury, then symptomatic support can be provided, but the treatments lack specificity and effectiveness in preventing kidney damage progression
Solution Approach 1:
The patent uses extracellular vesicles as intermediary carriers to deliver therapeutic agents specifically to kidney tissue. These vesicles act as mediators between the administered treatment and the target tissue, enabling precise delivery while protecting the therapeutic cargo from degradation and off-target effects.
Solution Approach 2:
The patent modifies extracellular vesicles to express kidney-specific targeting ligands on their surface, creating local specificity at the tissue level. This allows the treatment to concentrate its effect precisely where needed (injured kidney tissue) while minimizing systemic side effects.
2Adaptability or versatility
If extracellular vesicles are engineered for kidney targeting, then specific delivery can be achieved, but stable distribution within the body remains challenging
Solution Approach 1:
The patent creates composite extracellular vesicles that combine natural vesicle structures with engineered components (targeting ligands, therapeutic cargo, stabilizing molecules). This composite structure maintains the biological functionality of natural vesicles while adding stability and targeting capabilities through synthetic modifications.
Solution Approach 2:
The patent optimizes various parameters of the extracellular vesicles including surface charge, hydrophobicity, size distribution, and ligand density to achieve both stable circulation in the bloodstream and efficient kidney targeting. These parameter adjustments balance the competing requirements of stability and specificity.
3Measurement precision
If extracellular vesicles are modified with anchoring peptides for kidney targeting, then specific binding can be achieved, but the engineering process requires precise control for consistent drug delivery
Solution Approach 1:
The patent utilizes the natural homing capability of extracellular vesicles to navigate to injured tissue, combining this self-directed behavior with relatively simple surface modifications. The vesicles' inherent biological guidance systems perform much of the targeting work, reducing the complexity of engineered control mechanisms needed.
Solution Approach 2:
The patent performs preliminary engineering of the extracellular vesicles during their production phase, incorporating targeting ligands and therapeutic cargo before administration. This advance preparation ensures consistent targeting capability without requiring complex real-time control during treatment delivery.
Data Source
AI summary
The present invention discloses a method for the preparation and application of modified extracellular vesicles specifically targeted to the kidneys. These modified extracellular vesicles are derived from fibroblastic reticular cells in the mesentery tissue and express anti-inflammatory proteins after being modified with anchor peptides. By combining the extracellular vesicles secreted from fibroblastic reticular cells in the mesentery tissue with anchor peptides, the present invention ensures the effective targeting of the exosomes to the kidneys. Additionally, through genetic engineering of fibroblastic reticular cells, the exosomes secreted by these cells can carry the target molecule, anti-inflammatory protein CD5L, achieving precise targeted therapy for the kidneys. This innovative treatment strategy holds promising potential for the treatment of sepsis-associated acute kidney injury, bringing positive impacts to patients' health.